Pfizer

This study tests new versions of a vaccine to prevent severe diarrhea caused by C. diff bacteria. Healthy adults aged 50 and older who have never had a C. diff infection will receive either the vaccine or a placebo. Researchers will check how safe the vaccines are and how well th…

This study looks at how effective the Prevnar 20 (PCV20) vaccine is at preventing serious infections like pneumonia and invasive pneumococcal disease in people aged 65 and older. Researchers will analyze medical records from over 22 million Medicare beneficiaries to compare those…

This study tests a new vaccine (20vPnC) that protects against 20 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. About 200 healthy Chinese adults, children, and infants will receive the vaccine at different ages and schedules. Researchers w…

This study tests a new Lyme disease vaccine (VLA15) in healthy adults aged 18 to 44. Participants receive five shots over two years, with some getting the vaccine at different times and one shot being a placebo (saltwater). The goal is to see if the vaccine is safe and triggers a…

This study tests a new pneumococcal vaccine (PG4) in healthy infants to see if it is safe and helps their bodies fight off germs that cause pneumococcal disease. About 605 infants will receive either the new vaccine or a currently used one. Researchers will check for side effects…

This study looks at how well the RSV vaccine (ABRYSVO) given during pregnancy prevents serious RSV lung infections in babies. Researchers will review health records of infants hospitalized with breathing problems in Australia. No new treatments or visits are involved—just data an…

This study tests a new pneumococcal vaccine in adults 18 and older to see if it is safe and helps the body fight off pneumococcal disease. About 558 participants will receive either the new vaccine or a licensed one. The trial has four stages, with different age groups and vaccin…

This study checks how well the ABRYSVO vaccine works when given to pregnant people to protect their babies from RSV. Researchers will compare health outcomes of nearly 40,000 infants born to vaccinated versus unvaccinated mothers. The goal is to see if the vaccine reduces serious…

This study checks how well the PCV20 vaccine prevents pneumonia and other lung infections in adults 18 and older who are at higher risk. Researchers will look at health records from over 800,000 people at Kaiser Permanente Southern California, comparing those who got the vaccine …

This study looks at how well the ABRYSVO vaccine works when given to pregnant women to protect their babies from RSV, a serious lung infection. Researchers will review medical records of infants up to 6 months old in Western Pennsylvania over several RSV seasons. The goal is to s…

This early-stage study tests a new pneumococcal vaccine (PG4) to see if it is safe and tolerable in adults. About 380 healthy adults will receive either the experimental vaccine, a similar vaccine, a standard vaccine, or a placebo. Researchers will monitor side effects and blood …

This large Phase 3 study is testing a single shot of an experimental RSV vaccine in about 39,000 adults aged 60 and older. The goal is to see if the vaccine can prevent lower respiratory tract infections caused by RSV, a common virus that can be serious for older people. Particip…

This study tracks the safety of the Comirnaty (Pfizer) COVID-19 vaccine in 660 Korean adults after it was already approved for use. Researchers will record any side effects that happen within a week or a month after each dose. The goal is to catch any new or unexpected problems a…

This study checks the safety of the PREVENAR 20 vaccine in infants aged 2 to 6 months in Japan. About 1,100 babies will receive four doses as part of their routine shots. Researchers will track any side effects from the first dose until 28 days after the last dose.

This study examines how effective Pfizer's ABRYSVO vaccine is at preventing severe RSV infections in adults aged 60 and older. Researchers will analyze existing health records from routine doctor visits over several years, without actively enrolling participants. The goal is to u…

This study looks at how effective the ABRYSVO® vaccine is when given to pregnant women to protect their babies from RSV, a serious respiratory virus. Researchers will review medical records of infants up to 9 months old who were hospitalized with breathing problems. The goal is t…

This study tested an experimental drug called PF-06801591, which helps the immune system attack cancer cells. It involved 155 adults with advanced solid tumors or non-small-cell lung cancer who had already tried other treatments. The goal was to check the drug's safety, how the b…

This study is checking the safety of the drug Hympavzi in 50 people with hemophilia A or B who do not have inhibitors. Researchers are tracking any side effects that may be related to the drug. The goal is to see how safe Hympavzi is when used in everyday medical practice.

This study tests two oral medicines, vepdegestrant and samuraciclib, taken daily at home by adults with advanced or metastatic ER+ breast cancer that no longer responds to prior treatments. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth.…

This study offers continued treatment with lorlatinib for people with ALK- or ROS1-positive non-small cell lung cancer who are already benefiting from it in earlier Pfizer studies. The goal is to keep providing the drug while collecting more safety information. About 76 participa…

This study tests whether a newer targeted drug, lorlatinib, works better than the current standard drug, crizotinib, for people with advanced ALK-positive non-small cell lung cancer who have not had prior treatment. About 296 participants will receive either lorlatinib or crizoti…

This study tests two oral medications, vepdegestrant and PF-07220060, in people with advanced or metastatic ER+/HER2- breast cancer that has stopped responding to prior treatments. The goal is to see if the combination is safe and can shrink tumors. Participants take the pills at…

This study tests two doses (50 mg and 100 mg) of the daily pill ritlecitinib in about 550 people aged 12 and older with severe alopecia areata, a condition causing significant hair loss. Participants are randomly assigned to one of the two doses, and results are compared to data …

This study tests a new oral drug, vepdegestrant, combined with abemaciclib in people with advanced or metastatic ER+ breast cancer that no longer responds to previous treatments. About 37 adults will take both pills at home daily until their cancer worsens or side effects become …

This study tests an oral medication called tofacitinib in children aged 2 to 17 with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and ulcers. The goal is to see if the drug can reduce symptoms and bring about remission, meaning less bleeding…

This study tests whether adding two targeted drugs (encorafenib and cetuximab) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with a specific genetic type of advanced colorectal cancer (BRAF V600E, MSI-H/dMMR) that has spread and hasn't…

This study tests whether a new drug (PF-07220060) combined with fulvestrant works better than standard treatments for people with advanced or metastatic HR+/HER2- breast cancer that has worsened after prior CDK4/6 inhibitor therapy. About 333 adults will be randomly assigned to r…

This study tests a new medicine, PF-07868489, first in healthy adults to check safety and how the body processes it, then in people with pulmonary arterial hypertension (PAH) to see if it helps lower blood vessel resistance in the lungs. About 97 participants will take either the…

This study tests a new drug, MK-7119 (tucatinib), combined with two standard drugs (trastuzumab and capecitabine) in 66 people with advanced HER2+ breast cancer that has stopped responding to prior treatments. The main goal is to see if the combination can shrink tumors. Particip…

This study tests an oral drug called ritlecitinib for nonsegmental vitiligo, a condition that causes white patches on the skin. About 1,570 adults will be randomly assigned to take a low or high dose of the drug or a placebo daily for up to 2 years. The goal is to see if the drug…

This study looks back at the experiences of 35 adults with a specific type of advanced lung cancer (ROS1-positive NSCLC) that had stopped responding to other treatments. All participants took lorlatinib pills at home until their cancer progressed. Researchers will analyze how lon…

This study looks at the long-term safety and effectiveness of the drug elranatamab in people with multiple myeloma that has come back or stopped responding to other treatments. Researchers will track side effects like cytokine release syndrome and nerve problems, as well as how w…

This study tested whether adding enzalutamide to standard hormone therapy (leuprolide) can delay the spread of prostate cancer in men with high-risk, nonmetastatic disease that worsened after initial treatment. About 1,068 men participated. The main goal was to see how long until…

This study tracks the safety and effectiveness of Ngenla, a growth hormone injection, in over 500 children aged 3 and older with growth hormone deficiency. It is a post-marketing surveillance required by Korean regulators, lasting up to 6 years. The goal is to monitor side effect…

This phase 3 study compares a new drug, ARV-471, to the standard treatment fulvestrant in people with a common type of advanced breast cancer (ER+/HER2-) that has worsened after prior hormone therapy. About 624 adults whose cancer has spread or cannot be removed will be randomly …

This study tests a new drug called PF-07104091, alone or with other medicines, in people with advanced breast, lung, or ovarian cancer that has spread or come back. The goal is to find a safe dose and see if it shrinks tumors. About 157 adults will take part, and the drug is give…

This study monitors the safety and effectiveness of the drug ELREXFIO (elranatamab) in 150 Korean adults with multiple myeloma that has returned or not responded to at least three prior treatments. Researchers will track side effects and how well the drug controls the cancer in e…

This study tests whether adding two oral targeted drugs (encorafenib and binimetinib) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma that has a specific BRAF gene change. About 257 adults with untreated, advanced …

This study offers continued treatment with avelumab for people with advanced cancers like lung, ovarian, or bladder cancer who are already benefiting from it in earlier Pfizer studies. The goal is to keep providing the drug and monitor safety and survival. About 68 participants w…

This study tests a new medicine called vepdegestrant combined with palbociclib against the standard treatment (letrozole plus palbociclib) for people with advanced ER+/HER2- breast cancer that cannot be cured by surgery. Participants must not have received any prior cancer treatm…

This study looks at the long-term safety and effectiveness of the drug etrasimod for people with moderate to severe ulcerative colitis. Participants have already been in earlier studies and will continue taking etrasimod for up to two years. The goal is to see if the drug can hel…

This study tests a gene therapy called PF-06939926 in 114 boys with Duchenne muscular dystrophy (DMD), a severe muscle-weakening disease. Two-thirds of participants receive the gene therapy, while one-third get a placebo (with a chance to switch to the therapy after one year). Th…

This study looks at the safety of the drug TALZENNA in adults with a specific inherited breast cancer (BRCA mutation-positive, HER2-negative) that cannot be removed by surgery or has come back after chemotherapy. Only 3 participants who have not taken TALZENNA before will receive…

This study tests a new drug called elranatamab in people with multiple myeloma, a type of blood cancer, that has not responded to at least three prior treatments. The drug works by helping the body's immune cells attack the cancer cells. The main goal is to see how many patients …

This study follows one child with growth hormone deficiency (GHD) who is taking Ngenla for the first time. The goal is to check the drug's long-term safety and how well it helps growth. The child will be monitored until November 2027.

This study looks at the safety of BESPONSA, a drug already approved for children with a fast-growing blood cancer called ALL. About 10 children under 18 who have not used BESPONSA before will receive the drug as prescribed. Researchers will track side effects and watch for liver …

This study observes how patients with advanced non-small cell lung cancer and a specific gene mutation (EGFR-positive) respond to the drug dacomitinib in real-world settings in Taiwan. It includes 29 adults who took dacomitinib as their first treatment. Researchers track dosage c…

This study tests whether adding the drug talazoparib to standard treatment (enzalutamide) can slow the growth of metastatic castration-resistant prostate cancer (mCRPC). Over 1,000 men with this advanced cancer are participating. The goal is to see if the combination helps delay …

This study tests a daily pill called ritlecitinib in adults and teens with non-segmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the medicine can maintain or improve skin color over 52 weeks. Participants who already completed a year of …

This study tests a new drug (PF-07220060) combined with letrozole against standard treatments for people with HR-positive, HER2-negative advanced or metastatic breast cancer who have not had prior treatment for advanced disease. About 1,035 adults will be randomly assigned to rec…

This study follows 487 people with alopecia areata who are taking Litfulo capsules for the first time. Researchers want to confirm the drug's safety and how well it works in everyday use, not just in controlled trials. They will track side effects and measure hair regrowth using …

This study looks at the safety of the drug TALZENNA in men whose prostate cancer has spread and no longer responds to hormone therapy, and who have a BRCA gene mutation. Only one participant is being enrolled, and all will receive TALZENNA as prescribed. The main goal is to track…

This study tests a gene therapy (PF-06838435) for men with severe hemophilia B, a bleeding disorder. It aims to see if a single treatment can safely help the body produce its own clotting factor, reducing or stopping the need for regular infusions. Participants are followed for y…

This study tests whether adding the immunotherapy drug sasanlimab to standard BCG treatment can better control high-risk, early-stage bladder cancer and prevent it from coming back. About 1,068 participants with non-muscle invasive bladder cancer are involved, some receiving the …

This study tests a one-time gene therapy for adult men with moderate to severe hemophilia B, a bleeding disorder. The therapy delivers a working gene to help blood clot normally. Researchers will compare bleeding rates before and after treatment over 6 years. 51 participants will…

This study looks at how safe and effective the medicine CIBINQO is for treating atopic dermatitis (a type of eczema) in real-world Japanese medical practice. About 1,128 people are taking part. Researchers are tracking side effects and how well the drug clears skin symptoms.

This study offers continued access to the drug crizotinib for people with certain cancers (NSCLC, ALCL, or IMT) who are already benefiting from it in another Pfizer study that is ending. About 27 participants will be enrolled to receive ongoing treatment and to monitor safety. Th…

This study tests whether adding the drug talazoparib to standard treatment (enzalutamide) can help men with a certain genetic form of advanced prostate cancer live longer without their cancer getting worse. About 600 men with prostate cancer that has spread and has DNA repair gen…

This study tests a new oral drug, ARV-471, combined with ribociclib in people with advanced or metastatic ER+ breast cancer that no longer responds to prior treatments. About 20 adults will take both pills daily at home. Researchers will check safety and whether tumors shrink. Th…

This study offers continued treatment with the cancer drug palbociclib to people who have already benefited from it in earlier Pfizer studies. It includes 35 adults with breast or head/neck cancer. The main goal is to monitor safety and track any serious side effects over time.

This study tests whether adding an experimental drug (PF-06821497) to standard enzalutamide works better than standard treatments alone for men with metastatic castration-resistant prostate cancer that has progressed after abiraterone. About 600 participants will be randomly assi…

This early-stage study tests a new oral medication, PF-07985045, alone or with other cancer drugs, in people with advanced solid tumors that have a KRAS gene mutation. The cancers studied include non-small cell lung, colorectal, and pancreatic cancers. The main goals are to check…

This study tests a new drug, PF-07220060, in people with advanced solid tumors (breast, prostate, lung, and others) that have not responded to standard treatments. The drug is given alone or with hormone therapies to see if it is safe and shrinks tumors. About 362 participants wi…

This study follows 110 adults in Korea taking Vyndamax capsules for a heart condition called ATTR-CM, where abnormal proteins build up in the heart. Researchers will track side effects and check how well the drug works over 10 years in everyday medical practice. The goal is to en…

This study uses health records from nearly 99,000 adults in Ontario to see if the antiviral drug Paxlovid reduces the risk of severe COVID-19 outcomes like hospitalization or death. Researchers compared people who took Paxlovid with those who did not, tracking their health for up…

This early-phase study tests the safety of a drug called tucatinib in about 25 Chinese patients with advanced HER2+ breast, stomach, or colorectal cancers that have stopped responding to standard treatments. The main goal is to see what side effects occur and how the drug moves t…

This study tests a new drug called elranatamab (given as a shot) against the standard drug lenalidomide (taken as a pill) in people with newly diagnosed multiple myeloma who have already had a stem cell transplant. The goal is to see if elranatamab can keep the cancer from coming…

This study is checking how safe ATGAM is for people with moderate to severe aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. Only one person is taking part, and they will be watched for 24 weeks to see if any side effects happen. The goal is to …

This early-stage study tests two new drug combinations for people with multiple myeloma that has come back or stopped responding to treatment. About 59 adults will receive elranatamab (a shot under the skin) plus either carfilzomib and dexamethasone or another drug called maplirp…

This study aimed to see if a nasal spray called zavegepant could quickly stop migraine pain in adults. Participants would have used the spray at home for up to 4 migraine attacks. However, the study was withdrawn before enrolling anyone, so no results are available.

This study tests an experimental daily pill (PF-08049820) for adults with moderate to severe eczema (atopic dermatitis) who have not found a suitable prescription treatment. About 200 participants will take either the study drug or a placebo for 12 weeks, and researchers will tra…

This study collects information from medical records of about 350 adults with transthyretin amyloid cardiomyopathy (ATTR-CM) in Taiwan, Hong Kong, and Malaysia. Researchers will look at patient characteristics, treatments, and outcomes as part of routine care. No experimental dru…

This study aims to learn more about the symptoms and health effects of COVID-19 and influenza in adults. About 1,000 people with a positive test and mild symptoms will complete online surveys over six months. No treatment is given; the goal is to understand how these illnesses af…

This study looks at medical records from routine care to see how Palbociclib (a targeted therapy) is used in people with a certain type of advanced breast cancer (HR+/HER2-). Researchers want to understand how long patients stay on treatment and whether it delays the need for che…

This study follows 250 UK adults with migraine who already use rimegepant for acute attacks. Over 12 weeks, participants complete daily surveys to report how quickly they get pain relief and improvement in other symptoms. The goal is to understand how consistently rimegepant work…

This study looks at how a new medicine called PF-08049820, being developed for eczema, changes the way other drugs work in the body. Researchers will give healthy women birth control pills, a sedative, and a blood thinner, both with and without PF-08049820, to measure differences…

This study uses anonymous health records from California and Louisiana to see how effective the Pfizer-BioNTech COVID-19 vaccine is at preventing post-COVID conditions (long COVID). Researchers will also look at who gets vaccinated. The study includes adults with a COVID-19 diagn…

This study looks at anonymous health insurance records from Germany to learn more about a rare heart disease called ATTR-CM. Researchers want to see how long people live after diagnosis, how often they are hospitalized, and how common the disease is. No new treatments or visits a…

This study follows over 1,400 people with a common type of advanced breast cancer (HR+/HER2-) who are receiving standard first-line treatment with palbociclib plus hormone therapy. Researchers are collecting real-world data on how long the cancer stays controlled and overall surv…

This study looks at how the antifungal drug itraconazole changes the way the body processes a new medicine called PF-07248144. It involves 12 healthy adults who will take PF-07248144 alone and then with itraconazole. The goal is to understand safety and how the drug levels in the…

This early-stage study looks at how a single dose of an experimental medicine (PF-08653944) is absorbed when injected into the abdomen, thigh, or upper arm. It involves 54 overweight or obese adults who are otherwise healthy. The goal is to understand safety and how the body proc…

This study looks at the safety of the Abrysvo RSV vaccine in 1,100 adults aged 60 and older in Japan. Researchers track any side effects for 28 days after vaccination. The goal is to confirm the vaccine is safe when used in everyday medical practice.

This early-stage study looks at how a new medicine (PF-08049820) is processed by the body when taken alone or with a common stomach acid drug (rabeprazole). About 18 healthy Chinese adults will take both combinations by mouth, and researchers will measure medicine levels in the b…

This study looks at past medical records from France to see how doctors prescribe blood thinners to people with atrial fibrillation (an irregular heartbeat) who also have a high risk of stomach bleeding. It aims to understand which treatments are used and how often serious bleedi…

This study checks if new combination tablets of nirmatrelvir and ritonavir are absorbed by the body just like the current Paxlovid tablets. About 28 healthy adults will take single doses of both tablet types under fasting conditions. The goal is to see if the new tablets are bioe…

This study looks at how doctors in Italy currently treat a type of blood cancer called multiple myeloma when it stops responding to three main drug classes. Researchers will collect information from medical records of about 250 patients to understand which treatments are used and…

This study reviews medical records of about 300 people in the US with severe alopecia areata (an autoimmune disease causing hair loss) who started taking the drug ritlecitinib. Researchers want to see how effective the drug is in real-world settings, not just in controlled trials…

This study is tracking the safety and effectiveness of the drug XALKORI in 97 people with a certain kind of advanced lung cancer (ROS1-positive non-small cell lung cancer). The main goal is to find any unexpected side effects and see how well the drug works in everyday use. Parti…

This early-stage study tests a new medicine called PF-07999415 in 32 healthy adults aged 18 to 65. Participants receive a single shot and stay in a clinic for 2 weeks to monitor for side effects. The goal is to check safety and how the body processes the drug, not to treat any di…

This early-stage study tests a new medicine called PF-08049820, being developed for moderate to severe eczema (atopic dermatitis). The study involves 71 healthy adults aged 18 to 65 to check the drug's safety, how the body processes it, and whether food affects its absorption. Pa…

This study follows 319 young people under 21 who developed myocarditis or pericarditis (heart inflammation) within 21 days of receiving the Comirnaty COVID-19 vaccine. Researchers will track their heart health for up to 5 years using imaging and tests to understand long-term effe…

This study looks at how well the lung cancer medicine lorlatinib works when used as the first treatment for people with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer). Researchers will review medical records from a U.S. database to track how lon…

This study aims to understand the risks of birth defects, miscarriage, stillbirth, and low birth weight in pregnant women with migraine who took the drug rimegepant. Researchers will compare these outcomes to similar women who did not take the drug. The study is observational, me…

This study looks at how doctors prescribe treatments for ulcerative colitis (UC) and aims to create an updated treatment guide. Researchers will track 4,000 patients from a registry to see which treatments work best and when to switch therapies. The goal is to improve long-term o…

This study looks at insurance and vaccine records to see how well the yearly updated COVID-19 vaccines protect adults and children. Researchers will compare people who got the vaccine to those who did not, tracking doctor visits, emergency care, and hospital stays. No one receive…

This study looks back at medical records of 50 Chinese adults with ALK-positive advanced non-small cell lung cancer who started treatment with the drug lorlatinib. The goal is to understand patient characteristics and how the drug is used in real-world settings. No new treatments…

This study reviews existing medical records from Europe to understand how blood clots are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are …

This study is tracking the safety of the BNT162b2 COVID-19 vaccine (including the bivalent version) in 12,000 people in Korea who received the vaccine as part of routine care. Researchers are collecting information on side effects that happen within a week and up to 28 days after…